Impact of COVID-19 pandemic measures on hospitalizations and epidemiological patterns of twelve respiratory pathogens in children with acute respiratory infections in southern China

BMC Infectious Diseases, Journal Year: 2025, Volume and Issue: 25(1)

Published: Jan. 22, 2025

Abstract Objectives To investigate the impact of COVID-19 pandemic measures on hospitalizations and alterations persistence epidemiological patterns 12 common respiratory pathogens in children during after cessation “zero-COVID-19” policy southern China. Methods Respiratory specimens were collected from hospitalized with acute infections at Shenzhen Children’s Hospital January 2020 to June 2024. Twelve detected using multiplex PCR. Data demographic characteristics, pathogen detection rates, patterns, co-infections, ICU admission rates compared between ‘during COVID-19’ period (Phase 1: December 2022) ‘post 2: 2023 2024). Results In Phase 2, there was a significant increase average annual cases, higher median age affected children, increased co-infection 1. The most altered by pandemic. Human Parainfluenza Virus, Metapneumovirus, Bocavirus (HBOV), Coronavirus remained active 1, while Mycoplasma pneumoniae ( Mp ) Adenovirus (ADV) low, Syncytial Virus (RSV) lacked seasonal peak 2022. , ADV, RSV experienced outbreaks, ’s high prevalence continuing into showed out-of-season epidemics for two consecutive years. Influenza A (H1N1), (H3N2), InfB lost their 1 but reemerged regained characteristics 2023–2024. did not significantly differ phases, except HBOV, which had 2. Conclusion various varying degrees. Pathogens suppressed outbreaks or lifting non-pharmaceutical interventions, second year HBOV associated increasing post-pandemic era. Continuous monitoring these is essential understand duration effects inform effective response strategies.

Language: Английский

Epidemiological and clinical characteristics of adenovirus‐associated respiratory tract infection in children in Hangzhou, China, 2019−2024

Journal of Medical Virology, Journal Year: 2024, Volume and Issue: 96(10)

Published: Oct. 1, 2024

Abstract This study aimed to assess the impact of COVID‐19 on prevalence adenovirus (AdV) infection in children. retrospectively analyzed changes epidemiological and clinical features AdV‐associated respiratory infections children Hangzhou, China, between January 2019 July 2024. A total 771 316 samples were included study, positive rate was 6.10% (47 050/771 316). Among them, AdV highest 2019, reaching 11.29% (26 929/238 333), while rates remaining years 2% 9%. In terms seasonal epidemic characteristics, summer peak incidence, with peaking at around 16.95% (7275/45 268), followed by a gradual decline low‐level winter, 8.79% (8094/92 060). However, during period 2020−2024, season did not show any significant regularity. Gender analysis revealed that male patients generally greater than female patients. different age groups, population susceptible changed before after epidemic. early middle stages epidemic, mainly 2−5 old, whereas later 5−18 old. addition, main symptoms AdV‐positive from 2019−2024 tract fever. summary, has had certain AdV. These findings provide an important basis reference for prevention diagnosis AdV, especially context increasing age‐ gender‐specific public health strategies.

Language: Английский

Respiratory Syncytial Virus: A WAidid Consensus Document on New Preventive Options

Vaccines, Journal Year: 2024, Volume and Issue: 12(12), P. 1317 - 1317

Published: Nov. 25, 2024

Background/Objectives: Respiratory syncytial virus (RSV) is a leading cause of respiratory infections, particularly affecting young infants, older adults, and individuals with comorbidities. Methods: This document, developed as consensus by an international group experts affiliated the World Association Infectious Diseases Immunological Disorders (WAidid), focuses on recent advancements in RSV prevention, highlighting introduction monoclonal antibodies (mAbs) vaccines. Results: Historically, treatment options were limited to supportive care antibody palivizumab, which required multiple doses. Recent innovations have led development long-acting mAbs, such nirsevimab, provide season-long protection single dose. Nirsevimab has shown high efficacy preventing severe RSV-related lower tract infections (LRTIs) reducing hospitalizations ICU admissions. Additionally, new vaccines, RSVpreF RSVpreF3, target adults demonstrated significant LRTIs clinical trials. Maternal vaccination strategies also show promise providing passive immunity newborns, protecting them during most vulnerable early months life. document further discusses global burden RSV, its economic impact, challenges implementing these preventative different healthcare settings. Conclusions: The evidence supports integration both active (vaccines) immunization approaches effective tools mitigate public health impact RSV. combined use interventions could substantially reduce morbidity mortality across various age groups populations, emphasizing importance widespread efforts.

Language: Английский